MAM
Y&R’s chairman & CEO Edward Ney is no more
MUMBAI: Young & Rubicam former chairman and CEO, Edward N Ney, breathed his last on 8 January at 88 years old.
He had joined the company as a young account manager in 1951 and worked his way up to preside over the company as CEO from 1970 till 1986.
The industry attributes him for creating the agency’s integrated “whole egg” strategy which was later followed by others. In a press statement, WPP Group’s global CEO Martin Sorrell said that Ney “understood, probably more than anyone else, both the power of agency brands and, at the same time, the paradoxical need to bring them together… He understood it all and saw it sooner than most.”
Besides his work at Y&R, Ney was politically active as well. He became a member of the Council on Foreign Relations in 1974. In 1989, President George HW Bush nominated him as the United States Ambassador to Canada. He served in Ottawa until June 1992.
After his time as the ambassador, Ney returned to the agency as chairman.
Ney is survived by his wife, a son and two daughters.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
